A New Risk-Based Scoring Approach to Individualize Prophylaxis in Patients with Hemophilia A: Results from the...

Area of Science:

• Hematology
• Pharmacology
• Clinical Trials

Background:

• Optimal prophylaxis for hemophilia A lacks consensus, often relying on empirical regimens.
• The PREDICT study investigated a novel risk score to guide prophylaxis selection.
• Transitioning from standard half-life (SHL) factor VIII concentrates to damoctocog alfa pegol requires personalized strategies.

Purpose of the Study:

• To evaluate a baseline clinical risk score for guiding prophylactic regimen selection in hemophilia A patients.
• To assess the efficacy of individualized prophylaxis with damoctocog alfa pegol based on a risk-adapted approach.
• To determine if a risk-based scoring system improves bleeding outcomes and reduces treatment burden.

Main Methods:

• A prospective, multicenter study enrolled 21 participants (≥12 years) with hemophilia A on SHL prophylaxis.
• A risk score (low, medium, high) was assigned based on bleeding phenotype, treatment frequency, target joints, von Willebrand factor, and physical activity.
• Participants initiated damoctocog alfa pegol with individualized dosing based on risk score after an initial 4-week twice-weekly regimen.

Main Results:

• 12 out of 17 (70.6%) evaluable participants achieved a favorable outcome, defined by reduced annualized bleeding rate (ABR) and/or infusion frequency.
• Mean ABR decreased by 8.01, and mean infusion frequency reduced by 6.9 infusions/month.
• Active target joints decreased by 96% from baseline to study completion.

Conclusions:

• The PREDICT risk-based scoring system effectively guided individualized damoctocog alfa pegol prophylaxis.
• This approach led to improved bleeding control and a reduced treatment burden for most participants.
• Structured, risk-adapted strategies are beneficial for personalizing prophylaxis during transitions to newer factor concentrates.